Daré Bioscience (NASDAQ:DARE) Share Price Crosses Above Fifty Day Moving Average – Time to Sell?

Daré Bioscience, Inc. (NASDAQ:DARE)’s share price crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $3.39 and traded as high as $3.40. Daré Bioscience shares last traded at $3.30, with a volume of 16,248 shares.

Wall Street Analyst Weigh In

Separately, Maxim Group reiterated a “hold” rating on shares of Daré Bioscience in a research note on Wednesday, August 14th.

Daré Bioscience Price Performance

The stock has a market cap of $27.79 million, a price-to-earnings ratio of -0.86 and a beta of 1.39. The firm’s 50-day moving average is $3.39 and its 200 day moving average is $4.18.

Daré Bioscience (NASDAQ:DARE) last released its quarterly earnings data on Monday, August 12th. The biotechnology company reported $1.52 EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $2.09. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.60 million. On average, sell-side analysts forecast that Daré Bioscience, Inc. will post -0.27 EPS for the current year.

Hedge Funds Weigh In On Daré Bioscience

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC boosted its holdings in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the period. Renaissance Technologies LLC owned approximately 9.25% of Daré Bioscience worth $262,000 at the end of the most recent reporting period. 6.70% of the stock is currently owned by institutional investors and hedge funds.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.